An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), modified Process 60mg/kg in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency